GlassScriptPhysician profile
Derrick Grohe
NPI 1811763584
$1,812.55
in general payments reported to CMS, 2019-2025
19 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $13.54 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.84 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.55 | 2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $144.85 | 2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $113.32 | 2025 | Rezdiffra |
| Qol Medical, LLC | $97.67 | 2025 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.06 | 2025 | Xifaxan |
| Genzyme Corporation | $68.98 | 2025 | |
| Phathom Pharmaceuticals, INC. | $60.92 | 2025 | Voquezna |
| Janssen Biotech, INC. | $59.15 | 2025 | Tremfya |
| Pfizer INC. | $57.65 | 2025 | |
| Lilly USA, LLC | $45.10 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $34.70 | 2025 | |
| Vivus LLC | $33.81 | 2025 | Qsymia |
| Ipsen Biopharmaceuticals, INC | $29.98 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $26.67 | 2025 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $20.28 | 2025 | Vegzelma |
| Ardelyx, INC. | $20.25 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $14.23 | 2025 | Suflave, Sutab |
| Becton, Dickinson and Company | $13.54 | 2024 | Powerpicc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Grohe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.